Literature DB >> 17696954

Elevated matrilysin levels in bronchoalveolar lavage fluid do not distinguish idiopathic pulmonary fibrosis from other interstitial lung diseases.

Kirsi Vuorinen1, Marjukka Myllärniemi, Lauri Lammi, Päivi Piirilä, Paula Rytilä, Kaisa Salmenkivi, Vuokko L Kinnula.   

Abstract

Microarray studies have shown that matrilysin or matrix metalloproteinase (MMP)-7 is highly upregulated in the lungs of patients with idiopathic pulmonary fibrosis (IPF), but MMP-7 protein expression has not been systematically compared between IPF and other interstitial lung diseases. MMP-7 levels in bronchoalveolar lavage fluid (BALF) were compared to corresponding samples from nonspecific interstitial pneumonia (NSIP), sarcoidosis, and healthy controls. MMP-7 levels in the BALF were determined by ELISA and localization of MMP-7 in the lung tissue by immunohistochemistry. MMP-7 was similarly elevated in the BALF of all these disorders compared to healthy controls (p=0.007). Even control subjects with prolonged cough displayed a tendency towards elevated MMP-7 expression. There was a negative correlation between BALF MMP-7 levels and forced expiratory vital capacity (r=-0.348, p=0.02, n=42). In IPF lung, MMP-7 immunoreactivity appeared predominantly in the fibrotic parenchyma and arterial wall. In sarcoidosis and NSIP, prominent MMP-7 immunoreactivity was found in areas of inflammation. These results demonstrate that elevated BALF MMP-7 is not restricted to IPF alone but is also observed in other interstitial lung diseases and cannot be used as a differential diagnostic marker for IPF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17696954     DOI: 10.1111/j.1600-0463.2007.apm_697.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  13 in total

Review 1.  Idiopathic Pulmonary Fibrosis: A Genetic Disease That Involves Mucociliary Dysfunction of the Peripheral Airways.

Authors:  Christopher M Evans; Tasha E Fingerlin; Marvin I Schwarz; David Lynch; Jonathan Kurche; Laura Warg; Ivana V Yang; David A Schwartz
Journal:  Physiol Rev       Date:  2016-10       Impact factor: 37.312

2.  Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement.

Authors:  Ann Chen Wu; James P Kiley; Patricia J Noel; Shashi Amur; Esteban G Burchard; John P Clancy; Joshua Galanter; Maki Inada; Tiffanie K Jones; Jonathan A Kropski; James E Loyd; Lawrence M Nogee; Benjamin A Raby; Angela J Rogers; David A Schwartz; Don D Sin; Avrum Spira; Scott T Weiss; Lisa R Young; Blanca E Himes
Journal:  Am J Respir Crit Care Med       Date:  2018-12-15       Impact factor: 21.405

Review 3.  Peripheral blood biomarkers in idiopathic pulmonary fibrosis.

Authors:  Rekha Vij; Imre Noth
Journal:  Transl Res       Date:  2012-02-02       Impact factor: 7.012

Review 4.  Biomarkers in idiopathic pulmonary fibrosis.

Authors:  Yingze Zhang; Naftali Kaminski
Journal:  Curr Opin Pulm Med       Date:  2012-09       Impact factor: 3.155

Review 5.  Interfering with extracellular matrix degradation to blunt inflammation.

Authors:  Philip J O'Reilly; Amit Gaggar; J Edwin Blalock
Journal:  Curr Opin Pharmacol       Date:  2008-03-17       Impact factor: 5.547

6.  Hemoglobin α and β are ubiquitous in the human lung, decline in idiopathic pulmonary fibrosis but not in COPD.

Authors:  Nobuhisa Ishikawa; Steffen Ohlmeier; Kaisa Salmenkivi; Marjukka Myllärniemi; Irfan Rahman; Witold Mazur; Vuokko L Kinnula
Journal:  Respir Res       Date:  2010-09-13

7.  An alternative therapy for idiopathic pulmonary fibrosis by doxycycline through matrix metalloproteinase inhibition.

Authors:  Amartya Mishra; Parthasarathi Bhattacharya; Sumit Paul; Rantu Paul; Snehasikta Swarnakar
Journal:  Lung India       Date:  2011-07

8.  MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis.

Authors:  Ivan O Rosas; Thomas J Richards; Kazuhisa Konishi; Yingze Zhang; Kevin Gibson; Anna E Lokshin; Kathleen O Lindell; Jose Cisneros; Sandra D Macdonald; Annie Pardo; Frank Sciurba; James Dauber; Moises Selman; Bernadette R Gochuico; Naftali Kaminski
Journal:  PLoS Med       Date:  2008-04-29       Impact factor: 11.069

Review 9.  Molecular biomarkers in interstitial lung diseases.

Authors:  Angelo De Lauretis; Elisabetta A Renzoni
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

10.  A blood test for lung fibrosis.

Authors:  Peter J Barnes
Journal:  PLoS Med       Date:  2008-04-29       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.